Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders

Core Points - Aadi Bioscience, Inc. has received approval from stockholders for all proposals voted on during the Special Meeting held on February 28, 2025 [1][2][3][4] Group 1: Divestiture Proposal - The stockholders approved the sale of 100% of the outstanding shares of Aadi Subsidiary, Inc. to KAKEN INVESTMENTS INC., which includes all or substantially all assets related to the FYARRO® program [1] Group 2: PIPE Financing Proposal - The approval was granted for the issuance of 21,592,000 shares of common stock at a price of $2.40 per share, along with pre-funded warrants to purchase up to 20,076,500 shares at a price of$2.3999 per warrant [2] Group 3: Equity Plan Increase Proposal - An amendment to the 2021 Equity Incentive Plan was approved, increasing the shares available for issuance by 6,300,000 shares, raising the total from 2,000,284 to 8,300,284 shares, and increasing the annual automatic share reserve increase from 4% to 5% [3] Group 4: Non-Binding Advisory Vote - A non-binding advisory vote was approved regarding certain compensation that may be payable to named executive officers in connection with the divestiture [4]